SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-22-007805
Filing Date
2022-05-09
Accepted
2022-05-09 16:03:27
Documents
62
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q btai-20220331x10q.htm   iXBRL 10-Q 1417251
2 EX-10.1 btai-20220331xex10d1.htm EX-10.1 68905
3 EX-10.2 btai-20220331xex10d2.htm EX-10.2 18567
4 EX-31.1 btai-20220331xex31d1.htm EX-31.1 17833
5 EX-31.2 btai-20220331xex31d2.htm EX-31.2 17053
6 EX-32.1 btai-20220331xex32d1.htm EX-32.1 10383
7 EX-32.2 btai-20220331xex32d2.htm EX-32.2 8751
8 GRAPHIC btai-20220331x10q006.jpg GRAPHIC 65798
  Complete submission text file 0001558370-22-007805.txt   5070123

Data Files

Seq Description Document Type Size
9 EX-101.SCH btai-20220331.xsd EX-101.SCH 33189
10 EX-101.CAL btai-20220331_cal.xml EX-101.CAL 33662
11 EX-101.DEF btai-20220331_def.xml EX-101.DEF 125823
12 EX-101.LAB btai-20220331_lab.xml EX-101.LAB 326001
13 EX-101.PRE btai-20220331_pre.xml EX-101.PRE 245226
56 EXTRACTED XBRL INSTANCE DOCUMENT btai-20220331x10q_htm.xml XML 558299
Mailing Address 555 LONG WHARF DRIVE NEW HAVEN CT 06511
Business Address 555 LONG WHARF DRIVE NEW HAVEN CT 06511 203-643-8060
BioXcel Therapeutics, Inc. (Filer) CIK: 0001720893 (see all company filings)

IRS No.: 821386754 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38410 | Film No.: 22904814
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences